Whole-genome profiling of S6K1 and S6K2 high tumours, as well as after in vitro knock-down of the two kinases both resulted in significant differences, suggesting that isoform specific targeting of S6K1 or S6K2 may be valuable to allow further individualised breast cancer treatment regimens. This evidence concerns the gene RPS6KB1 and neoplasm.